Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Organon & Co.
(NY:
OGN
)
15.80
-0.66 (-4.01%)
Official Closing Price
Updated: 7:00 PM EST, Nov 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Organon & Co.
< Previous
1
2
3
Next >
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
November 05, 2024
From
Organon & Co.
Via
Business Wire
Organon Reports Results for the Third Quarter Ended September 30, 2024
October 31, 2024
From
Organon & Co.
Via
Business Wire
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
October 30, 2024
From
Organon & Co.
Via
Business Wire
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
October 28, 2024
From
Organon & Co.
Via
Business Wire
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
October 28, 2024
The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.
From
Roivant Sciences
Via
GlobeNewswire
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
October 09, 2024
From
Organon & Co.
Via
Business Wire
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
September 30, 2024
From
Organon & Co.
Via
Business Wire
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
September 18, 2024
From
Organon & Co.
Via
Business Wire
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
September 18, 2024
From
Roivant Sciences
Via
GlobeNewswire
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
August 20, 2024
From
Organon & Co.
Via
Business Wire
Organon Reports Results for the Second Quarter Ended June 30, 2024
August 06, 2024
From
Organon & Co.
Via
Business Wire
Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
July 09, 2024
From
Organon & Co.
Via
Business Wire
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
May 24, 2024
From
Organon & Co.
Via
Business Wire
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
May 07, 2024
From
Organon & Co.
Via
Business Wire
Organon Announces Proposed $1.0 Billion Senior Notes Offering
May 07, 2024
From
Organon & Co.
Via
Business Wire
Organon Reports Results for the First Quarter Ended March 31, 2024
May 02, 2024
From
Organon & Co.
Via
Business Wire
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
April 08, 2024
From
Organon & Co.
Via
Business Wire
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
April 08, 2024
From
Organon & Co.
Via
Business Wire
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
February 20, 2024
From
Organon & Co.
Via
Business Wire
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 15, 2024
From
Organon & Co.
Via
Business Wire
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
February 01, 2024
From
Organon & Co.
Via
Business Wire
Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
January 10, 2024
From
Organon & Co.
Via
Business Wire
Merck, the Dow's hottest stock, gets set to report Q4 financials
January 08, 2024
Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook
January 08, 2024
From
Organon & Co.
Via
Business Wire
Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023
From
Organon & Co.
Via
Business Wire
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
December 18, 2023
From
Organon & Co.
Via
Business Wire
Organon To Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Organon & Co.
Via
Business Wire
Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®
November 07, 2023
From
Samsung Bioepis
Via
GlobeNewswire
Organon Reports Results for the Third Quarter Ended September 30, 2023
November 02, 2023
From
Organon & Co.
Via
Business Wire
Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed
November 01, 2023
From
Organon & Co.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.